The Lancet Commission on prostate cancer: planning for the surge in cases

Nicholas D. James; Ian Tannock; James N'Dow; Felix Feng; Silke Gillessen; Syed Adnan Ali; Blanca Trujillo; Bissan Al-Lazikani; Gerhardt Attard; Freddie Bray; Eva Compérat; Ros Eeles; Omolara Fatiregun; Emily Grist; Susan Halabi; Áine Haran; Daniel Herchenhorn; Michael S. Hofman; Mohamed Jalloh; Stacy Loeb; Archie MacNair; Brandon Mahal; Larissa Mendes; Masood Moghul; Caroline Moore; Alicia Morgans; Michael Morris; Declan Murphy; Vedang Murthy; Paul L. Nguyen; Anwar Padhani; Charles Parker; Hannah Rush; Mark Sculpher; Howard Soule; Matthew R. Sydes; Derya Tilki; Nina Tunariu; Paul Villanti; Li Ping Xie

doi:10.1016/S0140-6736(24)00651-2

The Lancet Commission on prostate cancer: planning for the surge in cases

Nicholas D. James^* (Corresponding Author), Ian Tannock, James N'Dow, Felix Feng, Silke Gillessen, Syed Adnan Ali, Blanca Trujillo, Bissan Al-Lazikani, Gerhardt Attard, Freddie Bray, Eva Compérat, Ros Eeles, Omolara Fatiregun, Emily Grist, Susan Halabi, Áine Haran, Daniel Herchenhorn, Michael S. Hofman, Mohamed Jalloh, Stacy LoebArchie MacNair, Brandon Mahal, Larissa Mendes, Masood Moghul, Caroline Moore, Alicia Morgans, Michael Morris, Declan Murphy, Vedang Murthy, Paul L. Nguyen, Anwar Padhani, Charles Parker, Hannah Rush, Mark Sculpher, Howard Soule, Matthew R. Sydes, Derya Tilki, Nina Tunariu, Paul Villanti, Li Ping Xie

^*Corresponding author for this work

Applied Health Sciences

Research output: Contribution to journal › Review article › peer-review

28 Citations (Scopus)

4 Downloads (Pure)

Abstract

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal with these issues.

Original language	English
Pages (from-to)	1683-1722
Number of pages	40
Journal	The Lancet
Volume	403
Issue number	10437
Early online date	25 Apr 2024
DOIs	https://doi.org/10.1016/S0140-6736(24)00651-2
Publication status	Published - 3 May 2024

Bibliographical note

NDJ, RE, and CM are supported by the UK National Institute for Health and Care Research. Administrative support for the Commission was
provided by the Institute of Cancer Research (London, UK), and by Pip Wilkinson in particular. Patient input was provided via Movember.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(24)00651-2Licence: CC BY

James_etal_TLC_The_Lancet_Commission_VoR
https://creativecommons.org/licenses/by/4.0/
Final published version, 9.35 MBLicence: CC BY

Cite this

James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M., ... Xie, L. P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet, 403(10437), 1683-1722. https://doi.org/10.1016/S0140-6736(24)00651-2

James, ND, Tannock, I, N'Dow, J, Feng, F, Gillessen, S, Ali, SA, Trujillo, B, Al-Lazikani, B, Attard, G, Bray, F, Compérat, E, Eeles, R, Fatiregun, O, Grist, E, Halabi, S, Haran, Á, Herchenhorn, D, Hofman, MS, Jalloh, M, Loeb, S, MacNair, A, Mahal, B, Mendes, L, Moghul, M, Moore, C, Morgans, A, Morris, M, Murphy, D, Murthy, V, Nguyen, PL, Padhani, A, Parker, C, Rush, H, Sculpher, M, Soule, H, Sydes, MR, Tilki, D, Tunariu, N, Villanti, P & Xie, LP 2024, 'The Lancet Commission on prostate cancer: planning for the surge in cases', The Lancet, vol. 403, no. 10437, pp. 1683-1722. https://doi.org/10.1016/S0140-6736(24)00651-2

@article{089b2317513e46e2b9b25a5197665bee,

title = "The Lancet Commission on prostate cancer: planning for the surge in cases",

abstract = "Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal with these issues.",

author = "James, {Nicholas D.} and Ian Tannock and James N'Dow and Felix Feng and Silke Gillessen and Ali, {Syed Adnan} and Blanca Trujillo and Bissan Al-Lazikani and Gerhardt Attard and Freddie Bray and Eva Comp{\'e}rat and Ros Eeles and Omolara Fatiregun and Emily Grist and Susan Halabi and {\'A}ine Haran and Daniel Herchenhorn and Hofman, {Michael S.} and Mohamed Jalloh and Stacy Loeb and Archie MacNair and Brandon Mahal and Larissa Mendes and Masood Moghul and Caroline Moore and Alicia Morgans and Michael Morris and Declan Murphy and Vedang Murthy and Nguyen, {Paul L.} and Anwar Padhani and Charles Parker and Hannah Rush and Mark Sculpher and Howard Soule and Sydes, {Matthew R.} and Derya Tilki and Nina Tunariu and Paul Villanti and Xie, {Li Ping}",

note = "NDJ, RE, and CM are supported by the UK National Institute for Health and Care Research. Administrative support for the Commission was provided by the Institute of Cancer Research (London, UK), and by Pip Wilkinson in particular. Patient input was provided via Movember. ",

year = "2024",

month = may,

day = "3",

doi = "10.1016/S0140-6736(24)00651-2",

language = "English",

volume = "403",

pages = "1683--1722",

journal = "The Lancet",

issn = "0140-6736",

publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",

number = "10437",

}

TY - JOUR

T1 - The Lancet Commission on prostate cancer

T2 - planning for the surge in cases

AU - James, Nicholas D.

AU - Tannock, Ian

AU - N'Dow, James

AU - Feng, Felix

AU - Gillessen, Silke

AU - Ali, Syed Adnan

AU - Trujillo, Blanca

AU - Al-Lazikani, Bissan

AU - Attard, Gerhardt

AU - Bray, Freddie

AU - Compérat, Eva

AU - Eeles, Ros

AU - Fatiregun, Omolara

AU - Grist, Emily

AU - Halabi, Susan

AU - Haran, Áine

AU - Herchenhorn, Daniel

AU - Hofman, Michael S.

AU - Jalloh, Mohamed

AU - Loeb, Stacy

AU - MacNair, Archie

AU - Mahal, Brandon

AU - Mendes, Larissa

AU - Moghul, Masood

AU - Moore, Caroline

AU - Morgans, Alicia

AU - Morris, Michael

AU - Murphy, Declan

AU - Murthy, Vedang

AU - Nguyen, Paul L.

AU - Padhani, Anwar

AU - Parker, Charles

AU - Rush, Hannah

AU - Sculpher, Mark

AU - Soule, Howard

AU - Sydes, Matthew R.

AU - Tilki, Derya

AU - Tunariu, Nina

AU - Villanti, Paul

AU - Xie, Li Ping

N1 - NDJ, RE, and CM are supported by the UK National Institute for Health and Care Research. Administrative support for the Commission was provided by the Institute of Cancer Research (London, UK), and by Pip Wilkinson in particular. Patient input was provided via Movember.

PY - 2024/5/3

Y1 - 2024/5/3

N2 - Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal with these issues.

AB - Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal with these issues.

UR - http://www.scopus.com/inward/record.url?scp=85189703882&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(24)00651-2

DO - 10.1016/S0140-6736(24)00651-2

M3 - Review article

C2 - 38583453

AN - SCOPUS:85189703882

SN - 0140-6736

VL - 403

SP - 1683

EP - 1722

JO - The Lancet

JF - The Lancet

IS - 10437

ER -

The Lancet Commission on prostate cancer: planning for the surge in cases

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this